Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Alto Neuroscience, Inc. (ANRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ANRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.3% | Avg. Invested days 14 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.45M USD | Price to earnings Ratio - | 1Y Target Price 12.05 |
Price to earnings Ratio - | 1Y Target Price 12.05 | ||
Volume (30-day avg) 234870 | Beta - | 52 Weeks Range 1.60 - 17.55 | Updated Date 06/20/2025 |
52 Weeks Range 1.60 - 17.55 | Updated Date 06/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.88% | Return on Equity (TTM) -38.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -72862268 | Price to Sales(TTM) - |
Enterprise Value -72862268 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 27072100 | Shares Floating 17903611 |
Shares Outstanding 27072100 | Shares Floating 17903611 | ||
Percent Insiders 7.48 | Percent Institutions 77.52 |
Analyst Ratings
Rating 4.62 | Target Price 12.05 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alto Neuroscience, Inc.
Company Overview
History and Background
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for mental health. Founded to address the heterogeneity of mental illnesses, Alto uses brain biomarkers to identify patients most likely to respond to its novel therapies. Its approach is based on understanding the underlying neurobiology of mental health conditions.
Core Business Areas
- Drug Development: Alto focuses on the discovery and development of novel therapies for various mental health conditions.
- Biomarker Discovery: Alto identifies and validates biomarkers to stratify patients and predict treatment response.
- Clinical Trials: Alto conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Alto Neuroscience is led by a team of experienced pharmaceutical executives and scientists. The company's organizational structure consists of research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- ALTO-100: A novel treatment for depression. It is currently in clinical trials. Market share data not yet available as the product is in development. Competitors include SSRIs, SNRIs, and other antidepressants from companies like Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ).
- ALTO-203: A treatment for PTSD. Currently in clinical trials. Market share data not yet available as the product is in development. Competitors include SSRIs/SNRIs for PTSD by companies like Pfizer (PFE) and generic medications.
Market Dynamics
Industry Overview
The mental health therapeutics market is large and growing, driven by increasing awareness, prevalence of mental health disorders, and unmet medical needs. The market is characterized by intense competition and a growing focus on precision medicine approaches.
Positioning
Alto Neuroscience is positioned as a precision medicine company targeting specific patient populations with novel therapies. Its biomarker-driven approach provides a potential competitive advantage.
Total Addressable Market (TAM)
The total addressable market for mental health therapeutics is estimated to be billions of dollars. Alto is positioned to capture a significant share of this market by developing more effective and targeted therapies.
Upturn SWOT Analysis
Strengths
- Precision medicine approach
- Strong biomarker platform
- Experienced leadership team
- Pipeline of novel drug candidates
Weaknesses
- Clinical stage company with no approved products
- High R&D expenses
- Reliance on clinical trial success
- Limited revenue
Opportunities
- Expansion of biomarker platform to other mental health disorders
- Partnerships with pharmaceutical companies
- Regulatory approvals for drug candidates
- Increasing awareness of mental health
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Economic downturn affecting R&D funding
Competitors and Market Share
Key Competitors
- LLY
- PFE
- JNJ
- RDHL
Competitive Landscape
Alto Neuroscience differentiates itself through its precision medicine approach, targeting specific patient populations with novel therapies. However, it faces strong competition from larger, established pharmaceutical companies with greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial advancements.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include advancing clinical trials and expanding its biomarker platform.
Summary
Alto Neuroscience is an early-stage company pioneering precision medicine in mental health. Its biomarker-driven approach offers a competitive advantage, but the company faces typical risks associated with drug development. Successful clinical trials and potential partnerships are crucial for future growth, while competition from established pharmaceutical companies remains a significant challenge. Securing funding and navigating the regulatory landscape will also be essential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Clinical trial data
- SEC filings (if available)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alto Neuroscience, Inc.
Exchange NYSE | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2024-02-02 | Founder, Chairman of the Board, CEO & President Dr. Amit Etkin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://www.altoneuroscience.com |
Full time employees 76 | Website https://www.altoneuroscience.com | ||
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.